Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: A single centre experience with 12 allograft patients [2]

Bone Marrow Transplantation

Volumn 41, Issue 4, 2008, Pages 409-410

  Hui, C H ^a   Sia, H ^a   Mangos, H ^a   Horvath, N ^a   Lee, H ^a   Lewis, I ^a   Hughes, T ^a   To, L B ^a   Bardy, P ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; ETANERCEPT; FLUDARABINE; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; MYELOABLATIVE CONDITIONING; OUTCOMES RESEARCH; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICAL AUDIT; METHYLPREDNISOLONE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 40249100508     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705927     Document Type: Letter

References (7)

1. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanised anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
2. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-823.
3. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777-786.
4. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F et al Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135: 382-385.
5. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomised trial. Blood 2004; 104: 1559-1564.
6. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87-98.
7. Deeg JH. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126.